3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2009 Response to Dr. Goldstein and Colleagues' Comments. JAMA. In Press
2. 2009 Duration of Diabetes and type of diabetes treatment, increase the risk of hepatocellular carcinoma. Cancer. In Press
3. 2009 The association of family history of liver cancer with hepatocellular carcinoma: USA case-control study J Hepatology 50(2):334-41, 2009. e-Pub 10/2008. PMCID: PMCPMC2658718.
4. 2009 Survival among Asian American with Hepatitis and Hepatocellular Carcinoma Referred to a Comprehensive Cancer Center in Texas Bio Med Central Editorial 4(9):46, 2009. PMCID: PMCPMC2644315.
5. 2009 Reply to "No association between hepatitis B and pancreatic cancer in a prospective study in Korea" by Amy Berrington de Gonzalez, et.a J Clin Oncology 27(4):648-9, 2009. e-Pub 12/2008.
6. 2009 Amundadottir L, Kraft P, Stolzenberg-Solomon R, Fuchs SH, Petersen G, Hassan MM, Holly EA, Hunter DJ, Hutchinson A, Jackson A, Jacobs V, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz C, Li D, Hoover RN Hepatology 50(994), 2009.
7. 2009 Genome Wide Association Study Identifies ABO Blood Group Susceptibility Variants for Pancreatic Cancer Nature Genetics 41:986-90, 2009.
8. 2009 Association Between Hypothyroidism and Hepatocellular Carcinoma: A case-control study in the United States Hepatology 49(5):1563-70, 2009.
9. 2009 Antidiabetic Therapies Affect Risk of Pancreatic Cancer Gastroenterology 137(2):482-88, 8/2009.
10. 2009 Body Mass Index and Risk, Age of Onset, and Survival in Pancreatic Cancer Patients JAMA 301(24):2553-62, 6/2009.
11. 2009 Vascular Endothelial Growth Factor in the Management of Hepatocellular Carcinoma. A Review Literature. Cancer In Press
12. 2009 Pancreatitis and Pancreatic Cancer in Two Large Pooled Case-Control Studies. Cancer Causes and Controls In Press
13. 2008 Family History of Cancer and Risk of Neuroendocrine Tumors: Case-Control Study Cancer Epidemiol. Biomarkers & Prev 17(4):959-965, 2008.
14. 2008 XRCC2 and XRCC3 Gene Polymorphism and Risk of Pancreatic Cancer AM J Gastroenterology 103(2):360-367, 2008.
15. 2008 Effect of Different Types of Smoking and Synergism with Hepatitis C virus on Risk of Hepatocellular Carcinoma in American Men and Women: Case-Control Study Int J Cancer 123:1883-1891, 2008. NIHMSID: NIHMS93249.
16. 2008 Risk Factors Associated with Carcinoids: A U.S.-Based Case-Control Study. Int J Cancer 123(4):867-873, 2008.
17. 2008 Reply to passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer. Cancer 112(3):672-673, 2008.
18. 2008 Hepatitis B Virus and Pancreatic Cancer. J Clin Oncology 26(28):4557-4562, 10/2008. NIHMSID: NIHMS93233
19. 2008 Effect of Insulin-Like Growth Factor Gene Polymorphisms Alone or In Interaction with Diabetes on the Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers & Prevention 17(12):3467-73, 12/2008.
20. 2008 One Hundred Years After "Carcinoid": One Hundred Years After: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 38,825 Cases in the United States. JCO 26(18):2063-2072, 2008.
21. 2008 Interaction of the Cytochrome P4501A2, SULT1A1 and NAT Gene Polymorphisms with Smoking and Dietary Mutagen Intake in Modification of the Risk of Pancreatic Cancer Carcinogenesis 29(6):1184-1191, 2008.
22. 2007 Passive Smoking and Use of Non-Cigarette Tobacco Products in Association with Risk for Pancreatic Cancer A Case-Control Study. Cancer 109(12):2547-56, 2007.
23. 2007 Dietary Mutagen Exposure and Risk of Pancreatic Cancer Cancer Epidemiology, Biomarkers & Prevention 16(4):655-61, 2007.
24. 2007 Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 120(8):1748-54, 2007.
25. 2007 Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence Cancer 110(3):534-542, 2007.
26. 2007 Gluthathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer 109(5):840-848, 2007.
27. 2007 Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention 16(11):2379-2387, 2007.
28. 2007 HCV and Cholangiocarcinoma in USA, Case-Control Study Am J Gastroenterol 102:1-6, 2007.
29. 2007 K-Ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: In relation to cigarette smoking Pancreas 34(1):55-62, 2007
30. 2007 Population-based study of islet cell carcinoma. Ann Surg Oncol 14(12):3492-500, 2007.
31. 2007 Risk Factors of Pancreatic Cancer. AM J Gastroenterology 102:1-12, 2007.
32. 2006 Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 30(3):284-91, 2006.
33. 2006 Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer Carcinogenesis 27(1):103-11, 2006
34. 2006 Significant effects of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival Cancer Res 66(6):3323-30, 3/2006.
35. 2006 The XPD Asp(312)Asn and Lys(751)Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett, 2/2006.
36. 2005 Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial Cancer 103(4):749-55, 2/2005.
37. 2005 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer Cancer Epidemiol Biomarkers Prev 14(6):1470-6, 6/2005.
38. 2004 Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma Cancer 101(3):578-86, 8/2004.
39. 2004 Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: Relationship with prognosis. Dis Markers 20(6):333-43, 2004.
40. 2004 Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer Clin Cancer Res 10(12 Pt 1):4109-17, 6/2004.
41. 2003 Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis Hepatology 37(5):1165-71, 5/2003.
42. 2003 Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21(3):421-7, 2/2003.
43. 2002 Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer Carcinogenesis 23(2):301-6, 2/2002.
44. 2002 Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36(5):1206-13, 11/2002.
45. 2002 Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States J Clin Gastroenterol 35(3):266-9, 9/2002.
46. 2002 DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 513(1-2):37-48, 1/2002.
47. 2001 Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res 7(11):3375-80, 11/2001.
48. 2001 The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 33(2):123-6, 8/2001.
49. 2000 Hepatocellular Cancer: Epidemiology and Molecular Epidemiology of Hepatocellular Cancer. In: The Principles and Practice of Gastrointestinal Oncology. Oxford University Press
50. 2000 Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23(3):319-21, 6/2000.
51. 2000 Hepatocellular Cancer: Clinical Aspects and Management of Hepatocellular Cancer. In: The Principles and Practice of Gastrointestinal Oncology. Oxford University Press
52. 1998 Mutagen sensitivity as a susceptibility marker for human hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 7(7):567-70, 7/1998.

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.